التفاصيل البيبلوغرافية
| العنوان: |
Effects of cyclosporine A pretreatment of deceased organ donors on kidney graft function (Cis-A-rein): study protocol for a randomized controlled trial. |
| المؤلفون: |
Orban, Jean-Christophe, Fontaine, Eric, Cassuto, Elisabeth, Baumstarck, Karine, Leone, Marc, Constantin, Jean-Michel, Ichai, Carole, for the AzuRéa network, AzuRéa network |
| المصدر: |
Trials; 4/17/2018, Vol. 19 Issue 1, pN.PAG-N.PAG, 1p, 1 Chart |
| مصطلحات موضوعية: |
CYCLOSPORINE, ORGAN donors, KIDNEY transplantation, KIDNEY disease treatments, ISCHEMIA prevention |
| مستخلص: |
Background: Renal transplantation represents the treatment of choice of end-stage kidney disease. Delayed graft function (DGF) remains the most frequent complication after this procedure, reaching more than 30%. Its prevention is essential as it impedes early- and long-term prognosis of transplantation. Numerous pharmacological interventions aiming to prevent ischemia-reperfusion injuries failed to reduce the rate of DGF. We hypothesize that cyclosporine as an early preconditioning procedure in donors would be associated with decreased DGF.Methods: The Cis-A-rein study is an investigator-initiated, prospective, multicenter, double-blind, randomized, controlled study performed to assess the effects of a donor preconditioning with cyclosporine A on kidney grafts function in transplanted patients. After randomization, a brain dead donor will receive 2.5 mg kg-1 of cyclosporine A or the same volume of 5% glucose solution. The primary objective is to compare the rate of DGF, defined as the need for at least one dialysis session within the 7 days following transplantation, between both groups. The secondary objectives include rate of slow graft function, mild and severe DGF, urine output and serum creatinine during the first week after transplantation, rate of primary graft dysfunction, renal function and mortality at 1 year. The sample size (n = 648) was determined to obtain 80% power to detect a 10% difference for rate of DGF at day 7 between the two groups (30% of the patients in the placebo group and 20% of the patients in the intervention group).Discussion: Delayed graft function is a major issue after renal transplantation, impeding long-term prognosis. Cyclosporine A pretreatment in deceased donors could improve the outcome of patients after renal transplantation.Trial Registration: ClinicalTrials.gov, ID: NCT02907554 Registered on 20 September 2016. [ABSTRACT FROM AUTHOR] |
|
Copyright of Trials is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder